Viknesh Selvarajah News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Agents from three novel drug classes showed safety and hints of efficacy in patients with varying stages of chronic kidney disease in three phase 2 studies at the European Renal Association Congress.

United statesUniversity medical centerUnited kingdomBaylor college of medicineWolfgangc winkelmayerRonaldt gansevoortViknesh selvarajahEuropean renal association congressBoehringer ingelheimEuropean renal associationRestores renoprotectiveMore thanBaylor collegeRenal associationChronic renal failureHronic kidney failure